Form D · Biotechnology

CARISMA Therapeutics Inc.

Philadelphia, PA · CIK 0001708649

Offering snapshot reported Jan 5, 2021 · SEC filing

Reported sold
$38.3M
Offering amount: $70.4M
Investors reported
13
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 22, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 5, 2021Initial$38,269,452No comparison13SEC filing
Jul 8, 2020Amendment$52,924,976$23,825,006vs Jul 9, 201911SEC filing
Jul 9, 2019Amendment$29,099,970$3,000,005vs Jul 10, 201811SEC filing
Jul 10, 2018Initial$26,099,965No comparison11SEC filing
Apr 17, 2018Amendment$3,851,972$1,500,000vs Jun 14, 20177SEC filing
Jun 14, 2017Initial$2,351,972No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-385203

Source: Form D, filed Jan 5, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Margarita Chavez Director
Jacob Gunterberg Director
Michael Heffernan Director
Regina Hodits Director
Steven Kelly Director, Executive
Hy Levitsky Director
Dora Mitchell Director
Briggs Morrison Director
Eran Nadav Director
Bruce Peacock Director
Michael Poisel Director
Althea Stillman Director
Chidozie Ugwumba Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3675 Market Street Suite 200
Philadelphia, PA, 19104